Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Monte Rosa Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.monterosatx.com/...
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Markus Warmuth, MD
Number Of Employees: 134
Enterprise Value: $183,501,580
PE Ratio: -3.78
Exchange/Ticker 1: NASDAQ:GLUE
Exchange/Ticker 2: N/A
Latest Market Cap: $239,273,104
BioCentury | Mar 26, 2025
Product Development
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report
Plus:
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Oct 31, 2024
Deals
Trend watch: Degrader deals show glues are sticking
At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | Oct 29, 2024
Deals
Novartis adds another degrader, this time from Monte Rosa
Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Oct 16, 2024
Discovery & Translation
Science Spotlight: Better genomic predictors for Black AML patients
BioCentury’s roundup of translational innovations also includes a method for continuous base edits, plus updates from Monte Rosa and ImCheck
BioCentury | Jul 31, 2024
Management Tracks
Min Liu succeeds Yiping Li as CEO of JW
Plus: John Chin to retire as CBO from Antengene, and updates from ADARx, bit bio and Santhera
BioCentury | May 23, 2024
Emerging Company Profile
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assembly
BioCentury | May 17, 2024
Finance
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing
Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback
Items per page:
1 - 10 of 32